pembrolizumab + Poly-ICLC
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Colon Cancer
Conditions
Metastatic Colon Cancer, Solid Tumor
Trial Timeline
Jan 10, 2018 → Jul 29, 2022
NCT ID
NCT02834052About pembrolizumab + Poly-ICLC
pembrolizumab + Poly-ICLC is a phase 1/2 stage product being developed by Merck for Metastatic Colon Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02834052. Target conditions include Metastatic Colon Cancer, Solid Tumor.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Colon Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02834052 | Phase 1/2 | Completed |
Competing Products
20 competing products in Metastatic Colon Cancer